Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

  |  Issue: June 2019  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Eli Lilly and Company. News release: Lilly announces positive top-line results for COAST-X, a 52-week placebo-controlled study of Taltz (ixekizumab) in patients with non-radiographic axial spondyloarthritis. 2019 Apr 22.
  2. GSK. News release: GSK receives U.S. approval of Benlysta for intravenous use in children with lupus aged five years and above. 2019 Apr 26.

Related Articles